Regulation of progesterone receptor messenger ribonucleic acid by progestin in human endometrial stromal cells.
Down-regulation of the progesterone receptor (PR) by its ligand has been demonstrated in breast cancer cell lines and in the rat uterus. However, in the stromal cells of endometrium, reduction of the PR level is not apparent in the luteal phase of the menstrual cycle. The purpose of this study was to determine the effect of progestin on PR and PR mRNA in isolated human endometrial stromal cells. Western blot analysis showed that progesterone or medroxyprogesterone acetate increased the two isoforms, PR-A and PR-B, in stromal cells but reduced them in glandular epithelial cells. Progestin increased the PR-A and PR-B mRNA by 2- to > 10-fold in the stromal cells of 12 specimens measured by solution hybridization-ribonuclease protection assay. A time study showed that the increase in PR mRNA required at least a 2- to 3-day incubation with progestin and that the high mRNA levels were maintained or increased slightly beyond 10 days of progestin incubation. The stimulatory effect of progestin was inhibited by RU-486 and by cycloheximide, suggesting that the up-regulation requires ligand binding to PR and de novo protein synthesis. Progestin also increased the stability of PR mRNA in endometrial stromal cells. These results demonstrated for the first time that progestin exerts an up-regulation of PR by increasing the steady-state level of PR mRNA specifically in human endometrial stromal cells. The up-regulation of PR by progestin may be mediated in part by progestin-induced endometrial stromal cell factors such as estrogen and insulin-like growth factor-I, both of which stimulated the PR-A and PR-B mRNA in stromal cells.
Tseng
L
L
Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, 11794, USA. ltseng@mail.mos.sunysb.edu
Zhu
H H
HH
D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D004717:Endometrium / Q000166:cytology / Q000378:metabolism*; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D007700:Kinetics; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology; D011374:Progesterone / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000032:analysis / Q000235:genetics*; D017154:Stromal Cells / Q000378:metabolism
D006727:Hormone Antagonists; D011372:Progestins; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; D011980:Receptors, Progesterone; D003609:Dactinomycin; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol; D003513:Cycloheximide; D017258:Medroxyprogesterone Acetate